AR SB639

Requires health benefit plans offered in Arkansas to cover off-label use of intravenous immunoglobulin (IVIG) to treat pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS), effective January 1, 2022.

Applies to all health benefit plans including those offered by insurance companies, health maintenance organizations, hospital medical service corporations, and risk-based provider organizations under Medicaid, with specific exclusions for dental, disability, and workers' compensation plans.

Requires treatment plans to be established by the Childhood Post-infectious Autoimmune Encephalopathy Clinic at University of Arkansas for Medical Sciences in collaboration with Arkansas Children's Hospital.

Permits coverage to remain subject to standard policy deductions, copayments, and prior authorization reviews, and does not diminish other allowable benefits under health benefit plans.

Directs the Insurance Commissioner to develop and promulgate rules for implementation and administration of the coverage requirement.